• SIGN IN
  • GET HELP
  •  

    Webinar Details


    Event Type

    Live Online

    Date

    Wednesday, May 18, 2022

    Time

    10:30 AM - 11:45 AM ET

    Location

    PharmCon Webinar Studio (freeCE.com)

    Credits

    1.25 Contact Hour(s)

    Target Audience

    Pharmacist, Pharmacy Technician, Nurse

    Cost

    $30.00

    • Overview

      While much of the industry’s attention in 2021 was focused on FDA decisions about COVID vaccines and related therapies, a total of 50 new drugs were approved in 2021, outpacing the 10-year average for FDA drug approvals. This session provides a broad overview of the drugs approved in 2021, which includes significant growth in monoclonal antibody approvals. This session is designed to be a cursory overview of new approvals, bringing forward the most actionable and relevant pieces for those practicing in today’s pharmacies. The session includes a look at the COVID related emergency use authorizations and approvals introduced in 2021 and reviews some of the more controversial decisions and challenges of the year.


      Handouts

      Slide Document 22080L01_2pp.pdf
      Slide Document 22080L01_6pp.pdf





      Financial Support By

      PharmCon
    • Pharmacist

      Recognize the approved indication, common adverse effects and drug interactions for new drugs approved by the FDA in 2021.
      Identify important drug alerts by the FDA (Public Health Advisories) and implications for patient care.
      For selected new medications approved in 2021, identify the burden-to-benefit ratio of therapy.

      Pharmacy Technician

      Recognize the approved indication, common adverse effects and drug interactions for new drugs approved by the FDA in 2021.
      Identify important drug alerts by the FDA (Public Health Advisories) and implications for patient care.
      For selected new medications approved in 2021, identify the burden-to-benefit ratio of therapy.

      Nurse

      Recognize the approved indication, common adverse effects and drug interactions for new drugs approved by the FDA in 2021.
      Identify important drug alerts by the FDA (Public Health Advisories) and implications for patient care.
      For selected new medications approved in 2021, identify the burden-to-benefit ratio of therapy.
    • Repeat Presentation

      This presentation was last given on 4/13/2022 9:00 PM

      Future Airings

      Date Time
      Monday, June 13, 2022 9:00 PM View
      Wednesday, July 6, 2022 9:00 PM View

    • Activity Type

      Knowledge

      CE Broker

      20-900029

      Universal Activity Number

      Pharmacist 0798-0000-22-080-L01-P

      Pharmacy Technician 0798-0000-22-080-L01-T

      Nurse 0798-0000-22-080-L01-N

      ACPE PharmCon is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

      PharmCon, Inc. is an approved course provider for continuing education for nurses by the Florida Board of Nursing. PharmCon is also recognized by the California Board of Nursing as a provider of nursing programs.

      In order to obtain a Statement of Credit, attendees must respond to all randomly-generated participation checks and complete a program evaluation. Attendees may immediately print their Statement of Credit or leave them stored on the website.


    HARDWARE REQUIREMENTS
    Windows 8.1
    Windows 10
    Apple Mac OS X 10.13 or higher
    iOS 10+
    Android 4.3+


    SOFTWARE REQUIREMENTS
    Google Chrome
    Mozilla Firefox

    Log in locally; do not log in using a VPN, cloud server, remote desktop, etc.


    NETWORK REQUIREMENTS
    Broadband Internet Connection:
    T1, Hi-speed DSL or Cable
    4G cellular connection
     
     

    This continuing education activity is held as copyright by PharmCon. Through this notice, PharmCon. grants permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).




    Computer sharing is NOT permitted due to accreditation guidelines on activity monitoring. Credit is earned by one user per device.